- Previous Close
2.7600 - Open
2.9200 - Bid 1.9700 x 200
- Ask 3.4900 x 200
- Day's Range
2.7000 - 2.9200 - 52 Week Range
2.3600 - 60.8000 - Volume
9,101 - Avg. Volume
246,745 - Market Cap (intraday)
2.444M - Beta (5Y Monthly) 0.18
- PE Ratio (TTM)
-- - EPS (TTM)
-87.6800 - Earnings Date May 8, 2025 - May 12, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
170.73
Revelation Biosciences, Inc. operates as a clinical-stage biopharmaceutical company that focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was formerly known as Petra Acquisition, Inc. and changed its name to Revelation Biosciences, Inc. in January 2022. Revelation Biosciences, Inc. was incorporated in 2019 and is based in San Diego, California.
www.revbiosciences.comRecent News: REVB
View MorePerformance Overview: REVB
Trailing total returns as of 3/28/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: REVB
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: REVB
View MoreValuation Measures
Market Cap
2.44M
Enterprise Value
-4.05M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.52
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-52.93%
Return on Equity (ttm)
-264.85%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-15.04M
Diluted EPS (ttm)
-87.6800
Balance Sheet and Cash Flow
Total Cash (mrq)
6.5M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-8.34M